GILEAD SCIENCES, INC. Intangible Assets, Net (Excluding Goodwill)
GILEAD SCIENCES, INC. (GILD) had Intangible Assets, Net (Excluding Goodwill) of $14.03 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-06
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $14.03B.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $16.38B.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $16.98B.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $17.97B.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $14.03B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $16.38B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $16.98B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $17.97B 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $18.57B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $19.36B 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $19.95B 10-K · filed 2026-02-24 | |
| 2024-09-30 | $20.55B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $22.83B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $23.43B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $26.45B 10-K · filed 2025-02-28 | |
| 2023-09-30 | $27.15B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $27.75B 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $28.35B 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $28.89B 10-K · filed 2024-02-23 | |
| 2022-09-30 | $29.44B 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $29.89B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $30.33B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $33.45B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $33.90B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $34.34B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $34.78B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $33.13B 10-K · filed 2022-02-23 | |
| 2020-09-30 | $12.94B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $13.22B 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $13.50B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $13.79B 10-K · filed 2021-02-25 | |
| 2019-09-30 | $14.86B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $15.15B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $15.44B 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $15.74B 10-K · filed 2020-02-25 | |
| 2018-09-30 | $16.31B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $16.50B 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $16.80B 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $17.10B 10-K · filed 2019-02-26 | |
| 2017-09-30 | $8.34B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $8.55B 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $8.76B 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $8.97B 10-K · filed 2018-02-27 | |
| 2016-09-30 | $9.39B 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $9.71B 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $9.92B 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $10.25B 10-K · filed 2017-02-27 | |
| 2015-09-30 | $10.45B 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $10.66B 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $10.87B 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $11.07B 10-K · filed 2016-02-24 | |
| 2014-09-30 | $11.31B 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $11.51B 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $11.71B 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $11.90B 10-K · filed 2015-02-25 | $11.90B 10-K · filed 2014-02-25 |
| 2013-09-30 | $12.03B 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $12.06B 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $12.08B 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $11.74B 10-K · filed 2014-02-25 | |
| 2012-09-30 | $11.74B 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $11.75B 10-Q · filed 2012-08-01 | |
| 2012-03-31 | $11.77B 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $1.06B 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |